Why GH Research PLC’s (GHRS) Stock Is Up 7.56%
As of Thursday, July 16, GH Research PLC’s GHRS share price has surged by 7.56%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company’s lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Commentary & Analysis
Why GH Research PLC’s (GHRS) Stock Is Up 11.40%
As of Thursday, July 16, GH Research PLC’s GHRS share price has surged by 11.40%, which has investors questioning if this is right time to sell.Tudor Pop
Why GH Research PLC’s (GHRS) Stock Is Up 5.03%
As of Friday, June 26, GH Research PLC’s GHRS share price has surged by 5.03%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why GH Research PLC’s (GHRS) Stock Is Up 5.07%
As of Tuesday, June 09, GH Research PLC’s GHRS share price has surged by 5.07%, which has investors questioning if this is right time to sell.Jenna Brashear
Why GH Research PLC’s (GHRS) Stock Is Down 5.25%
As of Monday, June 08, GH Research PLC’s GHRS share price has dipped by 5.25%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | GHRS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,925.9 | $579.1 | 53% |
|
| Shares Out (Mil) | 62.0 | 43.0 | 53% |
|
| Institutional Ownership | 60.2% | 84.3% | 39% |
|
| Float (Mil) | 29.6 | 46.8 | 36% |
|
| Beta | 1.28 | 0.62 | 74% |
|
| Avg Daily Volume (000s) | 210 | 285 | 45% |
|
| Price Change (52-week) |
100.8% | 63.8% | 92% |
|
| Growth | GHRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (160.8%) | (1.4%) | 1% |
|
| EPS (5yr) | (118.2%) | 14.9% | 0 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 65.8% | (14.9%) | 96% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.303) | ($1.349) | ($1.902) | |
| Month Ago EPS | ($0.318) | ($1.403) | ($1.999) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | ($0.288) | ($1.324) | ($1.836) | |
| Year/Year Chg | (1.0%) | 70.5% | 166.4% | |
| Financials | GHRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $272 | na |
|
| Net Income (TTM) (Mil) | ($56) | ($11) | 15% |
|
| EPS (TTM) | ($0.909) | ($0.500) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($46) | ($6) | 9% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $4 | 37% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 10% |
|
| Enterprise Value (Q1) (Mil) | $1,221 | $522 | 43% |
|
| Valuation | GHRS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.60 | 2.73 | 84% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | GHRS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | 0.7% | na |
|
| ROA | (18.9%) | (24.6%) | 21% |
|
| ROE | (19.7%) | (19.7%) | 24% |
|
| Liabilities to Assets | 4.3% | 35.5% | 2% |
|
| F-Score | 2 | 3 | 7% |
|
GH Research PLC did not pass any screens on 7/31/2026.
